Cotadutide

DRUG4 trials

Sponsors

AstraZeneca

Conditions

Hepatic ImpairmentNon-alcoholic SteatohepatitisNon-cirrhotic Non-alcoholic Steatohepatitis With FibrosisType 2 Diabetes

Phase 1

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

CompletedNCT04208620

AstraZenecaType 2 Diabetes

Start: 2020-01-21End: 2020-07-08Updated: 2020-07-31

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

TerminatedNCT05517226

AstraZenecaHepatic Impairment

Start: 2022-09-06End: 2023-02-27Updated: 2023-03-21

A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

TerminatedNCT05668936

AstraZenecaNon-alcoholic Steatohepatitis

Start: 2023-01-03End: 2023-03-10Updated: 2023-04-05

Phase 2

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

CompletedNCT05364931

AstraZenecaNon-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Start: 2022-07-14End: 2024-04-19Updated: 2025-09-03

Related Papers

Safety/tolerability, efficacy and pharmacokinetics of 600‐μg cotadutide in <scp>Japanese</scp> type 2 diabetes patients with a body mass index of 25 kg/m <sup>2</sup> or higher: A phase I, randomized, double‐blind, placebo‐controlled study

Diabetes Obesity and Metabolism2023-06-1911 citations